Recipharm has announced the appointment of Vikas Gupta as President of its recently renamed biologics business unit, ReciBioPharm.
This appointment comes as Recipharm officially renames its biologics business unit following the acquisitions of advanced therapy CDMO, Arranta Bio; GenIbet, a specialist in the manufacture of biological clinical material; and virotherapy CDMO, Vibalogics.
“Vikas has a wealth of experience in the biologics sector and he’s the perfect candidate to drive the success of our ReciBioPharm business unit. The name ReciBioPharm places ‘Bio’ at the centre of our brand. This reflects the importance of our biologics offering to the whole Recipharm Group. This is an exciting time for our organisation and our customers can expect to see many new developments as ReciBioPharm continues to grow and evolve,” says Marc Funk, CEO, Recipharm.
Arranta Bio, GenIbet and Vibalogics bring established specialisms to ReciBioPharm. The business unit is well placed to offer capabilities in innovative technologies across gene therapy, viral vectors, mRNA, pDNA, oncolytic viruses and microbiome.
Vikas Gupta joins ReciBioPharm from Repligen Corporation, where he was Vice President & General Manager, Gene Therapy and Downstream Bioprocessing, and brings over 20 years’ experience in life sciences to the business unit.
“As President of ReciBioPharm, I will lead the team as we continue to support innovative biotechs advancing their therapies and bringing their drug products to market. With such a wealth of expertise and breadth of services now combined under one name, backed by the strength of the Recipharm Group, we offer a very compelling proposition for the biologics market. I look forward to helping promote this full service offering to our customers and prospects,” says Vikas Gupta.
Photo of Vikas Gupta: Recipharm